Insider buying
~$104K209K sh @ $0.4956
Traded Nov 13 · filed 5 days later
A major shareholder of Pasithea Therapeutics paid $104K out of pocket for Pasithea Therapeutics shares. Shares held went up 6% with this purchase.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 16, 2026 · Filed Nov 18, 2026
A major shareholder of Pasithea Therapeutics paid $291K out of pocket for Pasithea Therapeutics shares. Shares held went up 14% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$290,900
Shares × reported transaction price
Coastlands Capital LP, 10% owner's past purchases, 90 days after disclosure: 4 buys, median +18.4 pts vs S&P 500, beat it 3 of 4 times. Past results, not a forecast.
$100K–$500K
+14.4%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 0 months
Confirmed open-market purchases by the same insider in the available history
Yes
Compared with 2 earlier confirmed purchases
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
Closed at $0.50 on Nov 16, 2026, 71% above its 52-week low and 66% below its high, after a 10% rise over the previous 30 trading days
52-week range $0.2923 (Nov 21, 2025) to $1.47 (Nov 28, 2025), 18% of the way up, from 251 adjusted closes. 30 trading days earlier: $0.4549 on Oct 5, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
The largest open-market purchase by any KTTA insider in filings since 2022
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
Insider buying
Traded Nov 13 · filed 5 days later
A major shareholder of Pasithea Therapeutics paid $104K out of pocket for Pasithea Therapeutics shares. Shares held went up 6% with this purchase.
Insider buying
Largest insider buy since 2022Traded Nov 17 · filed 1 day later
A major shareholder of Pasithea Therapeutics paid $411K out of pocket for Pasithea Therapeutics shares. Shares held went up 19% with this purchase.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.